

# Global Drug Delivery Market - Trends and Forecast to 2022

<https://marketpublishers.com/r/GA6E1171AFDEN.html>

Date: October 2016

Pages: 728

Price: US\$ 4,200.00 (Single User License)

ID: GA6E1171AFDEN

## Abstracts

### Synopsis:

Global Drug Delivery Devices Market is expected to reach USD 1625.1 billion by 2022, at a CAGR of 8.0% during the forecast period of 2016 to 2022. The report contains 728 pages of exclusive premium insights with 960 tables and 54 figures.

Global Drug Delivery Devices Market is segmented based on product type, end-user, distribution channel, and geography.

On the basis of product type, the drug delivery devices market is segmented into oral, injectable, topical, pulmonary, nasal, ocular, implantable and transmucosal.

Based on end-users the market is segmented into hospitals, clinics, home healthcare, community healthcare, and others.

On the basis of distribution channel the market is segmented into hospital pharmacy, pharmacy stores, direct tenders, and online pharmacy.

The global drug delivery devices market is segmented into 5 regions such as North America, Europe, Asia-Pacific, South America and Middle East and Africa. These regions are further classified on the basis of country, into major countries such as U.S., Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.

Major Players Operating in this market:

Bayer AG, Johnson & Johnson, Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc. , Merck & Co., Sanofi, Antares Pharma, 3M, Becton Dickinson and Company, Nemera, Cima Labs, Inc., Dali Medical Devices, Alkermes, Foamis, Ypsomed, Skyepharma AG, Valeant Pharmaceuticals DSM Biomedical and Catalent, Inc. among others .

#### Regions Covered In The Scope Of The Report:

Global (North America (U.S., Canada, Mexico), Europe (Germany, France, U.K., Italy, Spain, Russia, Belgium, Netherlands, Switzerland, Turkey, Rest of Europe), Asia-Pacific (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of APAC), South America (Brazil, Rest of South America), Middle East and Africa( South Africa, Rest of MEA)).

## Contents

### 1 INTRODUCTION

- 1.1. OVERVIEW OF THE DRUG DELIVERY DEVICES MARKET
- 1.2. MARKET SEGMENTATION & COVERAGE
  - 1.2.1. CURRENCY AND PRICING
  - 1.2.2. LIMITATION
  - 1.2.3. STAKEHOLDERS

### 2 RESEARCH METHODOLOGY

- 2.1. KEY TAKEAWAYS
- 2.2. ARRIVING AT THE GLOBAL DRUG DELIVERY DEVICES MARKET SIZE
  - 2.2.1. MARKET CRACKDOWN APPROACH
  - 2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
  - 2.2.3. DATA TRIANGULATION
  - 2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
  - 2.2.5. PRODUCT PIPELINE ANALYSIS
  - 2.2.6. PORTER'S FIVE FORCES MATRIX
- 2.4. GLOBAL DRUG DELIVERY DEVICES MARKET: RESEARCH SNAPSHOT
- 2.5. ASSUMPTIONS

### 3 MARKET LANDSCAPE SUMMARY

### 4 PREMIUM INSIGHTS

- 4.1. OVERVIEW
- 4.2. GLOBAL DRUG DELIVERY DEVICES MARKET: KEY PRIMARY INSIGHTS
- 4.3. MARKET OVERVIEW
  - 4.3.1. DRIVERS
    - 4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASE SUCH AS DIABETES
    - 4.3.1.2. TECHNOLOGICAL DEVELOPMENT AND GROWTH IN BIOLOGICS
    - 4.3.1.3. INNOVATION AND DEVELOPMENT OF NEW DRUG TYPES
    - 4.3.1.4. BETTER HEALTHCARE SPENDING IN SOUTH ASIA AND AFRICA
  - 4.3.2. RESTRAINTS
    - 4.3.2.1. RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS
    - 4.3.2.2. HIGH PRICING OF PATENTED DRUGS AND LIMITED AVAILABILITY
  - 4.3.3. OPPURTUNITIES

- 4.3.3.1. RISING ACCEPTANCE OF SELF ADMINISTERING DRUGS
- 4.3.3.2. RISING DEMAND FOR BIOSIMILARS AND GENERIC DRUGS
- 4.3.3.3. RISING TREND OF ACQUISITION
- 4.3.3.4. FOCUS ON PATIENT NEEDS
- 4.3.3.5. DEVELOPING AND NEW EMERGING REVENUE POCKETS
- 4.3.4. THREATS
  - 4.3.4.1. PRODUCT RECALLS
  - 4.3.4.2. EXPENSIVE AND STRINGENT REGULATORY AND APPROVAL
  - 4.3.4.3. HIGH PRICING PRESSURE AND DECREASE IN CEILING PRICES
  - 4.3.4.4. PATENT EXPIRY AND PATENT CLIFF
- 4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES

## **5 EXECUTIVE SUMMARY**

## **6 DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE**

- 6.1. OVERVIEW
- 6.2. ORAL DRUG DELIVERY, BY FORM
  - 6.2.1. SOLID ORAL DRUGS, BY PRODUCT TYPE
    - 6.2.2.1. TABLETS
    - 6.2.2.2. CAPSULES
    - 6.2.2.3. POWDER
    - 6.2.2.4. PILLS
  - 6.2.2. LIQUID ORAL DRUGS, BY PRODUCT TYPE
    - 6.2.2.1. SOLUTIONS
    - 6.2.2.2. SYRUPS
  - 6.2.2. SEMI SOLID ORAL DRUGS, BY PRODUCT TYPE
    - 6.2.2.1. GELS
    - 6.2.2.2. EMULSIONS
    - 6.2.2.3. ELIXIRS
- 6.3. PULMONARY DRUG DELIVERY, BY PRODUCT TYPE
  - 6.3.1. METERED DOSE INHALERS (MDI)
  - 6.3.2. DRY POWDER INHALERS (DPI)
  - 6.3.3. NEBULIZERS
    - 6.3.3.1. JET NEBULIZERS
    - 6.3.3.2. ULTRASONIC NEBULIZERS
    - 6.3.3.3. SOFT MIST NEBULIZERS
- 6.4. INJECTABLE DRUG DELIVERY, BY PRODUCT TYPE
  - 6.4.1. INJECTABLE DRUG DELIVERY DEVICES, BY PRODUCT TYPE

- 6.4.1.1. CONVENTIONALS INJECTABLES, BY MATERIAL
  - 6.4.1.1.1. GLASS
  - 6.4.1.1.2. PLASTIC
- 6.4.2.2. CONVENTIONALS INJECTABLES, BY PRODUCT TYPE
  - 6.4.2.2.1. FILLABLE
  - 6.4.2.2.2. PRE-FILLED
- 6.4.3.3. CONVENTIONALS INJECTABLES, BY USABILITY
  - 6.4.3.3.1. REUSABLE SYRIGES
  - 6.4.3.3.2. DISPOSABLE SYRINGES
- 6.4.3.4. SELF INJECTION DEVICES
- 6.4.3.5. NEEDLE FREE INJECTORS
- 6.4.3.6. AUTOINJECTORS
- 6.4.3.7. PEN INJECTORS
- 6.4.3.8. WEARABLE INJECTORS
- 6.4.3.9. OTHERS
- 6.4.2. INJECTABLE DRUG DELIVERY FORMULATIONS, BY PRODUCT TYPE
  - 6.4.2.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS
  - 6.4.2.2. NOVEL DRUG DELIVERY FORMULATIONS
  - 6.4.2.3. LONG ACTING INJECTION FORMULATIONS
- 6.5. OPHTHALMIC DRUG DELIVERY, BY PRODUCT TYPE
  - 6.5.1. OCCULAR DRUG DELIVERY DEVICES, BY PRODUCT TYPE
    - 6.5.1.1. DRUG COATED CONTACT LENSES
    - 6.5.1.2. OCCULAR INSERTS
  - 6.5.2. OCCULAR DRUG DELIVERY FORMULATIONS, BY FORM
    - 6.5.2.1. LIQUID OCCULAR DRUG DELIVERY FORMULATIONS, BY TYPE
      - 6.5.2.1.1. EYE DROPS
      - 6.5.2.1.2. SPRAYS
    - 6.5.2.2. SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS, BY TYPE
      - 6.5.2.2.1. GELS
      - 6.5.2.2.2. OINTMENTS
- 6.6. NASAL DRUG DELIVERY, BY PRODUCT TYPE
  - 6.6.1. NASAL DROPS
  - 6.6.2. NASAL SPRAYS
  - 6.6.3. NASAL POWDERS
  - 6.6.4. NASAL GELS
- 6.7. TOPICAL DRUG DELIVERY, BY PRODUCT TYPE
  - 6.7.1. TRANSDERMAL DRUG DELIVERY DEVICES, BY PRODUCT TYPE
    - 6.7.1.1. TRANSDERMAL PATCHES
    - 6.7.1.2. TRANSDERMAL GELS

## 6.7.2. TOPICAL DRUG DELIVERY FORMULATIONS, BY FORM

### 6.7.2.1. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE

#### 6.7.2.1.1. SOLUTIONS

#### 6.7.2.1.2. SUSPENSIONS

### 6.7.2.2. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE

#### 6.7.2.2.1. GELS

#### 6.7.2.2.2. CREAMS

#### 6.7.2.2.3. OINTMENTS

#### 6.7.2.2.4. PASTES

#### 6.7.2.2.5. LOTIONS

### 6.7.2.3. SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE

#### 6.7.2.3.1. SUPPOSITORIES

#### 6.7.2.3.2. POWDERS

## 6.8. IMPLANTABLE DRUG DELIVERY, BY PRODUCT TYPE

### 6.8.1. ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES

### 6.8.2. PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES

## 6.9. TRANSMUCOSAL DRUG DELIVERY, BY PRODUCT TYPE

### 6.9.1. ORAL TRANSMUCOSAL DRUG DELIVERY, BY TYPE

#### 6.9.1.1. BUCCAL DRUG DELIVERY

#### 6.9.1.2. SUBLINGUAL DRUG DELIVERY

### 6.9.2. OTHER TRANSMUCOSAL DRUG DELIVERY, BY TYPE

#### 6.9.2.1. RECTAL TRANSMUCOSAL DRUG DELIVERY

#### 6.9.2.2. TRANSMUCOSAL TRANSMUCOSAL DRUG DELIVERY

## 7 DRUG DELIVERY DEVICES MARKET, BY END-USER

### 7.1. OVERVIEW

### 7.2. HOSPITALS

### 7.3. HOME HEALTHCARE

### 7.4. CLINICS

### 7.5. COMMUNITY HEALTHCARE

### 7.6. OTHERS

## 8 DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL

### 8.1. OVERVIEW

### 8.2. HOSPITAL PHARMACIES

### 8.3. PHARMACY STORES

### 8.4. DIRECT TENDERS

## 8.5. ONLINE PHARMACY

# 9 DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY

## 9.1. COUNTRYWISE DRUG DELIVERY DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

### 9.1.1. NORTH AMERICA

9.1.1.1. U.S.

9.1.1.2. CANADA

9.1.1.3. MEXICO

### 9.1.2. EUROPE

9.1.2.1. GERMANY

9.1.2.2. FRANCE

9.1.2.3. U.K.

9.1.2.4. ITALY

9.1.2.5. SPAIN

9.1.2.6. RUSSIA

9.1.2.7. TURKEY

9.1.2.8. BELGIUM

9.1.2.9. NETHERLANDS

9.1.2.10. SWITZERLAND

9.1.2.11. REST OF EUROPE

### 9.1.3. ASIA-PACIFIC (APAC)

9.1.3.1. JAPAN

9.1.3.2. CHINA

9.1.3.3. SOUTH KOREA

9.1.3.4. INDIA

9.1.3.5. AUSTRALIA

9.1.3.6. SINGAPORE

9.1.3.7. THAILAND

9.1.3.8. MALAYSIA

9.1.3.9. INDONESIA

9.1.3.10. PHILIPPINES

9.1.3.11. REST OF APAC

### 9.1.4. LATIN AMERICA

9.1.4.1. BRAZIL

9.1.4.2. REST OF LATIN AMERICA

### 9.1.5. MIDDLE EAST AND AFRICA

9.1.5.1. SOUTH AFRICA

- 9.1.5.2. REST OF MIDDLE EAST AND AFRICA
- 9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

## **10 DRUG DELIVERY DEVICES MARKET: COMPETITIVE LANDSCAPE**

- 10.1. GLOBAL DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
- 10.2. U.S. DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
- 10.3. EUROPE DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
- 10.4. APAC DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
- 10.5. SOUTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
- 10.6. MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
- 10.7. MERGERS & ACQUISITIONS
- 10.8. NEW PRODUCT DEVELOPMENT & APPROVALS
- 10.10. EXPANSIONS
- 10.10. REGULATORY CHANGES
- 10.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

## **11 DRUG DELIVERY DEVICES MARKET, COMPANY PROFILES**

- 11.1 BAYER AG
  - 11.1.1 COMPANY OVERVIEW
  - 11.1.2 SWOT ANALYSIS
  - 11.1.3 REVENUE ANALYSIS
  - 11.1.4 PRODUCT PORTFOLIO
  - 11.1.5 RECENT DEVELOPEMENTS
  - 11.1.5 DATA BRIDGE ANALYSIS
- 11.2 JOHNSON & JOHNSON
  - 11.2.1 COMPANY OVERVIEW
  - 11.2.2 SWOT ANALYSIS
  - 11.2.3 REVENUE ANALYSIS
  - 11.2.4 PRODUCT PORTFOLIO
  - 11.2.5 RECENT DEVELOPEMENTS
  - 11.2.5 DATA BRIDGE ANALYSIS
- 11.3 NOVARTIS AG
  - 11.3.1 COMPANY OVERVIEW
  - 11.3.2 SWOT ANALYSIS
  - 11.3.3 REVENUE ANALYSIS



- 11.3.4 PRODUCT PORTFOLIO
- 11.3.5 RECENT DEVELOPEMENTS
- 11.3.5 DATA BRIDGE ANALYSIS
- 11.4 PFIZER, INC.
  - 11.4.1 COMPANY OVERVIEW
  - 11.4.2 SWOT ANALYSIS
  - 11.4.3 REVENUE ANALYSIS
  - 11.4.4 PRODUCT PORTFOLIO
  - 11.4.5 RECENT DEVELOPEMENTS
  - 11.4.5 DATA BRIDGE ANALYSIS
- 11.5 F. HOFFMANN-LA ROCHE AG
  - 11.5.1 COMPANY OVERVIEW
  - 11.5.2 SWOT ANALYSIS
  - 11.5.3 REVENUE ANALYSIS
  - 11.5.4 PRODUCT PORTFOLIO
  - 11.5.5 RECENT DEVELOPEMENTS
  - 11.5.5 DATA BRIDGE ANALYSIS
- 11.6 GLAXOSMITHKLINE PLC
  - 11.6.1 COMPANY OVERVIEW
  - 11.6.2 SWOT ANALYSIS
  - 11.6.3 REVENUE ANALYSIS
  - 11.6.4 PRODUCT PORTFOLIO
  - 11.6.5 RECENT DEVELOPEMENTS
  - 11.6.5 DATA BRIDGE ANALYSIS
- 11.7 MERCK & CO.
  - 11.7.1 COMPANY OVERVIEW
  - 11.7.2 SWOT ANALYSIS
  - 11.7.3 REVENUE ANALYSIS
  - 11.7.4 PRODUCT PORTFOLIO
  - 11.7.5 RECENT DEVELOPEMENTS
  - 11.7.5 DATA BRIDGE ANALYSIS
- 11.8 ANTARES PHARMA, INC.
  - 11.8.1 COMPANY OVERVIEW
  - 11.8.2 SWOT ANALYSIS
  - 11.8.3 REVENUE ANALYSIS
  - 11.8.4 PRODUCT PORTFOLIO
  - 11.8.5 RECENT DEVELOPEMENTS
  - 11.8.5 DATA BRIDGE ANALYSIS
- 11.9 3M

- 11.9.1 COMPANY OVERVIEW
- 11.9.2 SWOT ANALYSIS
- 11.9.3 REVENUE ANALYSIS
- 11.9.4 PRODUCT PORTFOLIO
- 11.9.5 RECENT DEVELOPEMENTS
- 11.9.5 DATA BRIDGE ANALYSIS
- 11.9 SANOFI
  - 11.9.1 COMPANY OVERVIEW
  - 11.9.2 SWOT ANALYSIS
  - 11.9.3 REVENUE ANALYSIS
  - 11.9.4 PRODUCT PORTFOLIO
  - 11.9.5 RECENT DEVELOPEMENTS
  - 11.9.5 DATA BRIDGE ANALYSIS
- 11.9 BECTON, DICKINSON AND COMPANY
  - 11.9.1 COMPANY OVERVIEW
  - 11.9.2 SWOT ANALYSIS
  - 11.9.3 REVENUE ANALYSIS
  - 11.9.4 PRODUCT PORTFOLIO
  - 11.9.5 RECENT DEVELOPEMENTS
  - 11.9.5 DATA BRIDGE ANALYSIS
- 11.10 NEMERA
  - 11.10.1 COMPANY OVERVIEW
  - 11.10.2 SWOT ANALYSIS
  - 11.10.3 REVENUE ANALYSIS
  - 11.10.4 PRODUCT PORTFOLIO
  - 11.10.5 RECENT DEVELOPEMENTS
  - 11.10.5 DATA BRIDGE ANALYSIS
- 11.11 CIMA LABS, INC.
  - 11.11.1 COMPANY OVERVIEW
  - 11.11.2 SWOT ANALYSIS
  - 11.11.3 REVENUE ANALYSIS
  - 11.11.4 PRODUCT PORTFOLIO
  - 11.11.5 RECENT DEVELOPEMENTS
  - 11.11.5 DATA BRIDGE ANALYSIS
- 11.12 DALI MEDICAL DEVICES
  - 11.12.1 COMPANY OVERVIEW
  - 11.12.2 SWOT ANALYSIS
  - 11.12.3 REVENUE ANALYSIS
  - 11.12.4 PRODUCT PORTFOLIO

- 11.12.5 RECENT DEVELOPEMENTS
- 11.12.5 DATA BRIDGE ANALYSIS
- 11.13 ALKERMES
  - 11.13.1 COMPANY OVERVIEW
  - 11.13.2 SWOT ANALYSIS
  - 11.13.3 REVENUE ANALYSIS
  - 11.13.4 PRODUCT PORTFOLIO
  - 11.13.5 RECENT DEVELOPEMENTS
  - 11.13.5 DATA BRIDGE ANALYSIS
- 11.14 FOAMIS
  - 11.14.1 COMPANY OVERVIEW
  - 11.14.2 SWOT ANALYSIS
  - 11.14.3 REVENUE ANALYSIS
  - 11.14.4 PRODUCT PORTFOLIO
  - 11.14.5 RECENT DEVELOPEMENTS
  - 11.14.5 DATA BRIDGE ANALYSIS
- 11.15 YPSOMED
  - 11.15.1 COMPANY OVERVIEW
  - 11.15.2 SWOT ANALYSIS
  - 11.15.3 REVENUE ANALYSIS
  - 11.15.4 PRODUCT PORTFOLIO
  - 11.15.5 RECENT DEVELOPEMENTS
  - 11.15.5 DATA BRIDGE ANALYSIS
- 11.16 SKYEPHARMA AG
  - 11.16.1 COMPANY OVERVIEW
  - 11.16.2 SWOT ANALYSIS
  - 11.16.3 REVENUE ANALYSIS
  - 11.16.4 PRODUCT PORTFOLIO
  - 11.16.5 RECENT DEVELOPEMENTS
  - 11.16.5 DATA BRIDGE ANALYSIS
- 11.17 VALEANT PHARMACEUTICALS
  - 11.17.1 COMPANY OVERVIEW
  - 11.17.2 SWOT ANALYSIS
  - 11.17.3 REVENUE ANALYSIS
  - 11.17.4 PRODUCT PORTFOLIO
  - 11.17.5 RECENT DEVELOPEMENTS
  - 11.17.5 DATA BRIDGE ANALYSIS
- 11.18 DSM BIOMEDICAL
  - 11.18.1 COMPANY OVERVIEW

11.18.2 SWOT ANALYSIS  
11.18.3 REVENUE ANALYSIS  
11.18.4 PRODUCT PORTFOLIO  
11.18.5 RECENT DEVELOPEMENTS  
11.18.5 DATA BRIDGE ANALYSIS

#### 11.19 CATALENT, INC.

11.19.1 COMPANY OVERVIEW  
11.19.2 SWOT ANALYSIS  
11.19.3 REVENUE ANALYSIS  
11.19.4 PRODUCT PORTFOLIO  
11.19.5 RECENT DEVELOPEMENTS  
11.19.5 DATA BRIDGE ANALYSIS

## **12 APPENDIX**

## **13 ABOUT DATA BRIDGE MARKET RESEARCH**

## I would like to order

Product name: Global Drug Delivery Market - Trends and Forecast to 2022

Product link: <https://marketpublishers.com/r/GA6E1171AFDEN.html>

Price: US\$ 4,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA6E1171AFDEN.html>